Detralex, 1000 mg 30 pcs

Detralex has venotonic and angioprotective properties. The drug reduces venous distensibility and venous stasis, reduces capillary permeability and increases their resistance. The results of clinical studies confirm the pharmacological activity of the drug with respect to indexes of venous hemodynamics.

A statistically significant dose-dependent effect of the drug Detralex has been demonstrated for the following venous plethysmographic parameters: venous capacity, venous distensibility, and venous emptying time.

The optimal dose-effect ratio is observed when taken at a dose of 1000 mg per day.

Detralex increases venous tone: venous occlusion plethysmography has been shown to decrease time of venous emptying. In patients with signs of severe microcirculatory disorders after therapy with Detralex an increase of capillary resistance evaluated by angiostereometry was noted (statistically significant compared to placebo).

Therapeutic effectiveness of the drug Detralex in the treatment of chronic diseases of the lower limbs veins and in the treatment of hemorrhoids has been proved.

Indications

Varicose veins, Pain, Stiffness and pain in the legs, Hemorrhoids, Anal fissures, Cramps of the calf muscles, Trophic ulcers

Detralex is indicated for the treatment of symptoms of chronic vein diseases (elimination and relief of symptoms).

• Therapy of symptoms of venous and lymphatic insufficiency:
  • pain;
  • cramps of the lower extremities;
  • feeling of heaviness and tumescence in the legs;
  • “tired” legs.
• Treatment of manifestations of venous-lymphatic insufficiency:
  • edema of the lower extremities;
  • trophic changes in the skin and subcutaneous tissue;
  • venous trophic ulcers.
• Symptomatic therapy of acute and chronic hemorrhoids.
  

Active ingredient

Purified micronized flavonoid fraction (diosmin, flavonoids in terms of hesperidin)

Composition

1 tablet contains purified micronized flavonoid fraction 1000 mg, including:

• diosmin 900 mg (90%)
• flavonoids converted to hesperidin 100 mg (10%)

30 oral pills in a pack

How to take, the dosage

The drug is administered orally.

The recommended dose for veno-lymphatic insufficiency is 1 tablet/day, preferably in the morning, with meals.

The risk on the tablet is intended to be divided solely for the purpose of facilitating swallowing.

The duration of treatment may be several months (up to 12 months). If symptoms recur, the course of treatment may be repeated at the doctor’s recommendation.

The recommended dose for acute hemorrhoids is 3 tablets daily (1 tablet in the morning, afternoon and evening) for 4 days and then 2 tablets daily (1 tablet in the morning and evening) for the next 3 days.

The recommended dose for chronic hemorrhoids is 1 tablet/day.

Interaction

No drug interactions of the drug Detralex® have been reported.

The attending physician should be informed of all medications taken by the patient.

Special Instructions

It is recommended that the patient consult a physician before starting the use of the drug Detralex®.

In case of exacerbation of hemorrhoids, administration of the drug Detralex® does not replace specific treatment of other anal disorders. The duration of treatment should not exceed the periods specified in the section “Dosage regimen”. If symptoms do not disappear after the recommended course of therapy, a proctologist should be examined and a further therapy should be chosen.

In the presence of venous circulatory disorders, the maximum effect of therapy is achieved by a combination of therapy with a healthy (balanced) lifestyle: it is advisable to avoid prolonged exposure to the sun, prolonged periods of standing on feet and it is also recommended to reduce excessive body weight. Walking and, in some cases, wearing special stockings helps to improve blood circulation.

The patient should see a physician immediately if the condition worsens or does not improve with treatment.

The drug does not affect the ability to drive or perform work requiring rapid mental and physical reactions.

Contraindications

• High sensitivity to the active ingredients or excipients in the drug.
• In the absence of data on excretion of the drug in the breast milk, nursing women are not recommended to take the drug.

.

Side effects

The side effects of the drug Detralex® observed during clinical trials were mild in severity. Gastrointestinal disorders (diarrhea, dyspepsia, nausea, vomiting) were mostly observed.

The following side effects have been reported during the use of the drug Detralex® in the following grading: Very common (≥1/10), common (≥1/100, < 1/10), infrequent (≥1/1000, < 1/100), rare (≥1/10 000, < 1/1000), very rare (< 10 000), unspecified frequency (frequency cannot be calculated from available data).

CNS side: rarely – dizziness, headache, general malaise.

Gastrointestinal disorders: frequent – diarrhea, dyspepsia, nausea, vomiting; infrequent – colitis; unspecified frequency – abdominal pain.

Skin: rare – rash, pruritus, urticaria; unspecified frequency – isolated swelling of the face, lips, eyelids; in exceptional cases – angioedema.

The patient must be informed that if any undesirable reactions and sensations occur during therapy, including those not mentioned in the instructions, as well as changes in laboratory parameters, the physician must be informed.

Overdose

No cases of overdose have been described.

Patients should seek medical attention immediately if they overdose.

Similarities

Venarus, Phlebaven, Venolife Duo, Detravenol, Diosmin+Hesperidin, Troxactiv